X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-daiichi-astrazeneca-drug-treatment-solid-tumors-2024-04-05/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139
https://www.indianpharmapost.com/news/biocon-biologics-partners-with-sandoz-australia-for-biosimilars-trastuzumab-and-bevacizumab-15257
https://www.ema.europa.eu/en/documents/overview/herwenda-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2023/09/18/2744414/0/en/Sandoz-receives-positive-CHMP-opinion-for-breast-and-gastric-cancer-biosimilar-trastuzumab.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-pharma-slashes-price-of-breast-cancer-drug-trastuzumab/articleshow/101015785.cms
https://www.prnewswire.com/news-releases/us-food-and-drug-administration-issues-complete-response-letter-for-byondis-vic-trastuzumab-duocarmazine-301824573.html
https://health.economictimes.indiatimes.com/news/pharma/biocon-biologics-facility-gets-eu-gmp-certification-for-bevacizumab/99851350
https://www.businesswire.com/news/home/20221222005382/en/Seagen-Announces-FDA-Accelerated-Approval-of-TUKYSA%C2%AE-tucatinib-in-Combination-with-Trastuzumab-for-People-with-Previously-Treated-RAS-Wild-Type-HER2-Positive-Metastatic-Colorectal-Cancer
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nppa-revises-ceiling-prices-of-128-formulations/articleshow/97033906.cms
https://www.globenewswire.com//news-release/2022/12/06/2568751/0/en/INmune-Bio-Inc-Reports-Combination-Therapy-with-INB03-Overcomes-Resistance-to-Trastuzumab-Deruxtecan-in-MUC4-expressing-HER2-Breast-Cancer.html
https://www.globenewswire.com/news-release/2022/10/04/2527406/0/en/Roche-receives-FDA-approval-for-first-companion-diagnostic-to-identify-patients-with-HER2-low-metastatic-breast-cancer-eligible-for-ENHERTU.html
https://endpts.com/enhertu-strikes-again-with-a-phiii-success-in-another-breast-cancer-population/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139
https://www.prnewswire.com/news-releases/ema-validates-marketing-authorization-application-for-trastuzumab-duocarmazine-syd985-in-her2-positive-metastatic-breast-cancer-301587559.html
https://www.prnewswire.com/news-releases/fda-accepts-byondis-biologics-license-application-for-vic--trastuzumab-duocarmazine-syd985-in-her2-positive-metastatic-breast-cancer-301584658.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/roche-launches-antibody-drug-for-breast-cancer-in-india/articleshow/91526195.cms
http://www.pharmafile.com/news/608613/nice-draft-guidance-recommends-tucatinib-advanced-breast-cancer
https://www.globenewswire.com/news-release/2022/02/15/2385698/0/en/Celularity-Receives-Orphan-Drug-Designation-from-U-S-FDA-for-its-NK-Cell-Therapy-CYNK-101-in-Development-for-the-First-Line-Treatment-of-Advanced-HER2-neu-Positive-Gastric-and-Gast.html
https://www.globenewswire.com/news-release/2022/01/18/2368416/0/en/Celularity-Receives-Fast-Track-Designation-from-U-S-FDA-for-its-NK-Cell-Therapy-CYNK-101-in-Development-for-the-First-Line-Treatment-of-Advanced-HER2-neu-Positive-Gastric-and-Gastr.html
https://www.expresspharma.in/cadila-pharmaceuticals-expands-oncology-portfolio-launches-tarzed/
https://www.globenewswire.com/news-release/2021/12/22/2356483/0/en/Sandoz-submits-Marketing-Authorization-Application-for-proposed-biosimilar-trastuzumab-to-EMA.html
https://www.globenewswire.com/news-release/2021/12/20/2355646/0/en/Sandoz-submits-Biologics-License-Application-for-proposed-biosimilar-trastuzumab-to-US-FDA.html
https://www.globenewswire.com/news-release/2021/12/10/2350025/37568/en/Merus-Presents-Updated-Analysis-of-Zenocutuzumab-Trastuzumab-and-Vinorelbine-in-Patients-with-HER2-Metastatic-Breast-Cancer-at-the-San-Antonio-Breast-Cancer-Symposium.html
https://www.asiaone.com/business/henlius-4th-biologics-bevacizumab-biosimilar-hanbeitai-approved-national-medical-products
https://www.prnewswire.com/news-releases/actinium-presents-first-ever-data-with-a-cd47-immunotherapy-in-combination-with-a-her2-directed-targeted-radiotherapy-in-solid-tumors-at-the-society-for-immunotherapy-for-cancer-sitc-conference-301422935.html
https://www.europeanpharmaceuticalreview.com/news/164614/nice-does-not-recommend-tucatinib-in-new-draft-guidance/
https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/
https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/
https://www.prnewswire.com/news-releases/byondis-esmo-late-breaking-presentation-confirms-adc-vic--trastuzumab-duocarmazine-syd985-superior-to-physicians-choice-in-pre-treated-locally-advanced-or-metastatic-her2-positive-breast-cancer-301379760.html
https://www.evaluate.com/vantage/articles/news/snippets/esmo-2021-mahogany-loses-its-polish-macrogenics
https://www.globenewswire.com/news-release/2021/09/12/2295419/0/en/Samsung-Bioepis-Announces-Five-year-Follow-up-Results-for-ONTRUZANT-trastuzumab-in-Early-or-Locally-Advanced-HER2-Positive-Breast-Cancer-at-the-European-Society-for-Medical-Oncolog.html
https://www.businesswire.com/news/home/20210607005374/en/Greenwich-LifeSciences-Publishes-Additional-Positive-Safety-Data-from-GP2-Phase-IIb-Trial-at-ASCO-2021-Confirming-that-GP2-Treatment-to-Prevent-Metastatic-Breast-Cancer-Recurrence-is-Well-Tolerated
http://www.pharmatimes.com/news/uk_cancer_centre_to_offer_breast_cancer_treatment_at_home_1368444
http://www.pharmatimes.com/news/uk_cancer_centre_to_offer_breast_cancer_treatment_at_home_1368444
https://www.nice.org.uk/news/article/nice-draft-guidance-provides-cancer-drugs-fund-first-in-europe-access-to-new-treatment-option-for-advanced-breast-cancer
Market Place
Share 
